Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA

N Engl J Med. 2020 Sep 24;383(13):1199-1202. doi: 10.1056/NEJMp2004889.
No abstract available

MeSH terms

  • Cardiovascular Diseases / chemically induced*
  • Controlled Clinical Trials as Topic / standards
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Approval*
  • Drug-Related Side Effects and Adverse Reactions
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / therapeutic use
  • Patient Safety
  • United States
  • United States Food and Drug Administration

Substances

  • Hypoglycemic Agents